A significant genetic determinant for Alzheimer’s disease, known as APOE4, is now understood to initiate profound changes within brain cells, potentially years before the onset of discernible cognitive impairments. This influential genetic variant, present in a substantial portion of the global population, has been identified as a key contributor to the risk of developing Alzheimer’s. Recent scientific inquiry has elucidated a molecular pathway through which APOE4 exerts its influence, offering novel insights into the disease’s progression and potential therapeutic avenues.
Researchers at the Gladstone Institutes have meticulously mapped a specific molecular cascade that may elucidate the early functional disruptions in neurons associated with the APOE4 genotype. Their groundbreaking findings not only shed light on the fundamental mechanisms at play but also suggest a promising strategy for mitigating these detrimental cellular changes. The study, which utilized sophisticated mouse models, was recently published in the esteemed journal Nature Aging.
The core discovery centers on the observation that APOE4 significantly elevates the production of a protein designated as Nell2. Elevated levels of Nell2 were found to correlate with a reduction in neuronal size and an atypical increase in their electrical activity, a phenomenon termed hyperactivity. Crucially, the research demonstrated a direct link between the degree of this early brain hyperactivity in young mice and the severity of memory deficits they exhibited in later life. This correlation suggests that these subtle, precognitive alterations are not merely incidental but serve as significant predictors of future cognitive decline.
In a pivotal experiment, the research team successfully modulated Nell2 production. By reducing the levels of this protein, even in adult mice already carrying the APOE4 variant, the scientists observed a remarkable reversal of the observed neuronal abnormalities. Neurons began to regain their normal size and their electrical firing patterns normalized. This successful intervention offers a compelling prospect: future therapeutic interventions targeting Nell2 could potentially offer a means to counteract the adverse effects of APOE4, thereby mitigating the elevated risk of Alzheimer’s disease in individuals who carry this genetic predisposition.
Dr. Misha Zilberter, a principal staff research scientist at Gladstone and a senior author of the study, emphasized the novelty of their findings. "To the best of our knowledge, this is the first study that has directly examined what APOE4 does to the function of neurons at different ages," he stated. He further elaborated on the significance of their observations, noting, "We found fundamental changes in brain circuits occurring in young mice that still had normal learning and memory, and importantly, that those changes predicted the development of cognitive deficits at older ages." This underscores the critical insight that neuronal dysfunction can precede overt symptomatic presentation.
The APOE gene exists in three common forms: APOE2, APOE3, and APOE4. While APOE2 is associated with a reduced risk of Alzheimer’s, and APOE3 is considered neutral, APOE4 stands out as the strongest known genetic risk factor for the disease. Approximately one in every four individuals carries at least one copy of the APOE4 variant. Its prevalence among individuals diagnosed with Alzheimer’s disease is notably high, estimated to be between 60% and 75%. This genetic association has long been a focal point of Alzheimer’s research, prompting extensive investigation into its underlying biological mechanisms.
Dr. Yadong Huang, associate director of the Gladstone Institute of Neurological Disease and another senior author of the study, described the research as a significant advancement. "This study is a big breakthrough for the field of Alzheimer’s research," he remarked. "It opens the door to a better understanding of how APOE4 alters the function of neurons at a young age to increase risk of cognitive decline, and to the development of therapies that could block the detrimental effects of APOE4 early on." This sentiment highlights the dual impact of the research: deepening fundamental understanding and paving the way for targeted therapies.
Previous research had already indicated a pattern of heightened brain activity in human carriers of APOE4, even before middle age. This early hyperactivity has been consistently linked to an increased likelihood of later cognitive decline. However, the precise mechanisms by which APOE4 instigated these cellular changes and how they ultimately contributed to memory impairments remained largely elusive. The current study provides a crucial piece of this puzzle by dissecting the molecular underpinnings of this early dysfunction.
To unravel these mechanisms, the researchers meticulously analyzed brain activity recordings from young mice and examined individual neurons derived from their brains. The results were striking: young mice genetically predisposed with APOE4 exhibited markedly excessive neuronal firing within specific regions of the hippocampus. The hippocampus is a brain structure critically involved in learning and memory formation, making its dysfunction a central concern in Alzheimer’s pathology.
Intriguingly, these same hippocampal regions identified as hyperactive in the APOE4 mice have also been observed to display elevated activity in human APOE4 carriers. This cross-species consistency lends considerable weight to the findings and their translational relevance. Dennis Tabuena, PhD, a scientist co-mentored by Zilberter and Huang and the first author of the paper, elaborated on this predictive aspect: "We found that the extent of hyperactivity in young mice predicted how poorly they performed on spatial learning and memory tests later in life." This predictive power is a cornerstone of understanding disease trajectory.
For comparative analysis, the scientists contrasted the APOE4 mice with a control group of mice carrying APOE3, a genetic variant of the APOE gene that is not associated with an increased risk of Alzheimer’s disease in humans. The study revealed a distinct morphological difference: neurons within the affected hippocampal regions of APOE4 mice were consistently smaller than those in APOE3 mice. Smaller neurons are generally more susceptible to external stimuli, making them more prone to firing excessively, a finding that aligns with the observed hyperactivity.
Furthermore, the research indicated that while hippocampal neurons in APOE3 mice did exhibit increased excitability over time, this phenomenon only became apparent in the animals at a much later stage of life, mimicking a more typical aging process. In contrast, the APOE4 variant appeared to accelerate this process significantly. As Dr. Huang explained, "This suggests APOE4 accelerates a process that resembles normal aging, and could explain why people with the gene variant are more likely to develop Alzheimer’s disease earlier in life." This accelerated aging of neural circuits is a key contributor to the earlier onset of symptoms.
A significant aspect of the investigation focused on the origin of these APOE4-driven cellular changes. While APOE protein is produced by various brain cells, astrocytes – which provide support to neurons – are the primary producers of APOE in a healthy brain. This led to a long-standing hypothesis that astrocytes were largely responsible for the link between APOE4 and Alzheimer’s risk. However, the new findings challenge this assumption.
The research strongly suggests that the hippocampal hyperactivity associated with APOE4 is predominantly driven by APOE4 produced within the neurons themselves, rather than by extraneuronal sources. This conclusion is supported by targeted genetic manipulations. "When we deleted the APOE4 gene from astrocytes, nothing changed," Dr. Zilberter reported. "But when we deleted it from neurons, the cells became larger and started functioning normally again." This indicates that the critical detrimental effects are cell-intrinsic.
The identification of Nell2 as a key player in this molecular cascade opened up a new avenue for potential therapeutic intervention. The researchers delved deeper to uncover the specific molecular pathway responsible for the smaller size and increased excitability of APOE4 neurons. They meticulously examined gene expression patterns within individual cells across various hippocampal cell types.
This comprehensive analysis pointed directly to Nell2, which was found in unusually high concentrations within neurons carrying the APOE4 variant. To further investigate Nell2’s role, the scientists employed CRISPRi, a precise gene-editing technique that can reduce gene activity without permanently altering the DNA sequence. Using this method, they suppressed Nell2 production in hippocampal neurons of adult APOE4 mice.
The outcome was transformative. Following the reduction of Nell2 levels, the neurons not only increased in size but also displayed a significant decrease in their excitability. This demonstrated that elevated Nell2 is indeed the direct culprit behind the excessive neuronal activity observed in brains expressing APOE4. While Nell2 had not been previously studied in the context of APOE4, prior research had identified increased Nell2 levels in the brains of Alzheimer’s patients, with higher concentrations correlating with poorer cognitive function, further solidifying its implicated role in the disease.
The therapeutic implications of these findings are particularly encouraging. "What’s exciting about Nell2 is that we were able to reverse the disease manifestations in adult mice by lowering its level," Dr. Huang enthused. "That tells us the damage is not irreversible, and that there may be a window for intervention even after disease processes have been triggered." This suggests that therapeutic strategies aimed at reducing Nell2 levels could potentially halt or even reverse some of the early pathological changes associated with APOE4, offering hope for a new class of treatments for individuals at risk of or in the early stages of Alzheimer’s disease.
The research was made possible through substantial funding from various national health institutes, including the National Institute on Aging (R01AG061150, R01AG087323, R01AG092390, R01AG085468, R01AG055682, R01AG071697, P01AG073082, F32AG0859612), the National Institute of Neurological Disorders and Stroke (K99NS134734), and the National Center for Research Resources (C06 RR018928).
About the Author
